Combined treatment of HCV infection: Is there a need for meta-analysis?

Hepatology Research

Volumn 20, Issue 3, 2001, Pages 359-371

  Bacosi, Marco ^a   Patsouri, Mosha ^a   Miglioresi, Lucia ^a   Patrizi, Franca ^a   Russo, Francesca ^a   Ricci, Giovanni L ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

HCV; Interferon; Ribavirin

Indexed keywords

INTERFERON; PLACEBO; RIBAVIRIN;

ARTICLE; BIOCHEMISTRY; CLEARANCE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG RESPONSE; HEPATITIS C; HUMAN; META ANALYSIS; MONOTHERAPY; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RELAPSE; SIDE EFFECT; TREATMENT FAILURE; VIRUS GENOME;

EID: 0034971475     PISSN: 13866346     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1386-6346(00)00142-X     Document Type: Article

References (22)

1. Epidemiology of hepatitis C
2. Therapy of chronic hepatitis C: Overview
3. Drug therapy: The treatment of chronic viral hepatis
4. Meta-analysis as a source of evidence in gastroenterology: A critical approach
5. Meta-analysis: An introduction and point of view
6. Meta-analysis: When and how
7. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C
8. Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C
9. Sequential versus concomitant administration of ribavirin and interferon Alfa-n3 in patients with chronic hepatitis C not responding to interferon alone: Results of a randomized controlled trial
10. Long-term efficacy of ribavirin plus interferon alfa in the treatment of chronic hepatitis C
11. Combination antiviral therapy with ribavirin and interferon alfa in interferon alfa relapsers and non-responders: Italian experience
12. Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus
13. Randomised, double-blind, placebo-controlled trial of interferon alpha-2b with and without ribavirin for chronic hepatitis C
14. Interferon alpha-2B and ribavirin in combination for patients with chronic hepatitis C who failed to respond to, or relapsed after, interferon alpha therapy: A randomized trial
15. Retreatment of non-responder or relapser chronic hepatitis C patients with interferon plus ribavirin vs interferon alone
16. Interferon-alpha plus ribavirin in chronic hepatitis C resistant to previous interferon-alpha course: Results of a randomized multicenter trial
17. Ribavirin and interferon-alpha combination therapy vs interferon-alpha alone in the retreatment of chronic hepatitis C: A randomized clinical trial
18. Meta-analysis in clinical trials
19. Meta-analysis in clinical research
20. Large trials vs meta-analysis of smaller trials: How do their results compare?
21. Gastric mucosa as an additional extrahepatic localization of hepatitis c virus: Viral detection in gastric low-grade lymphoma associated with autoimmune disease and in chronic gastritis
22. Current therapy for chronic hepatitis C